These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 5670861)

  • 21. Registry of adverse drug reactions.
    JAMA; 1968 Jan; 203(1):31-4. PubMed ID: 5694080
    [No Abstract]   [Full Text] [Related]  

  • 22. Medical use of cannabis in Australia: "medical necessity" defences under current Australian law and avenues for reform.
    Martin C
    J Law Med; 2014 Jun; 21(4):875-99. PubMed ID: 25087368
    [TBL] [Abstract][Full Text] [Related]  

  • 23. European Medicines Agency assesses safety reporting at Roche.
    Marshall H
    Lancet Oncol; 2012 Aug; 13(8):e331. PubMed ID: 23024993
    [No Abstract]   [Full Text] [Related]  

  • 24. Clinical pharmacology at university medical centers. I. Functions and organization.
    Wardell WM
    J Clin Pharmacol; 1974 Jul; 14(7):309-24. PubMed ID: 4845389
    [No Abstract]   [Full Text] [Related]  

  • 25. Adverse drug reactions: definition of the problem.
    Dunlop D
    Am J Epidemiol; 1971 Nov; 94(5):403-4. PubMed ID: 5120537
    [No Abstract]   [Full Text] [Related]  

  • 26. Drugs policy will not change as long as UK government refuses to acknowledge the need for change.
    Robertson R; McAuley A; Macleod J; Strang J; McCallum A
    BMJ; 2018 Jun; 361():k2604. PubMed ID: 29925647
    [No Abstract]   [Full Text] [Related]  

  • 27. Identification of discrepancies between adverse drug reactions coded by medical records technicians and those reported by the pharmacovigilance team in pediatrics: An intervention to improve identification, reporting, and coding.
    Soyer J; Necsoiu D; Desjardins I; Lebel D; Bussières JF
    Arch Pediatr; 2019 Oct; 26(7):400-406. PubMed ID: 31611146
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety of newly approved drugs: implications for prescribing.
    Temple RJ; Himmel MH
    JAMA; 2002 May; 287(17):2273-5. PubMed ID: 11980528
    [No Abstract]   [Full Text] [Related]  

  • 29. Post-marketing surveillance of adverse reactions to new medicines.
    Wilson AB
    Br Med J; 1977 Oct; 2(6093):1001-3. PubMed ID: 922357
    [No Abstract]   [Full Text] [Related]  

  • 30. An analysis of Australian adverse drug events.
    Malpass A; Helps SC; Runciman WB
    J Qual Clin Pract; 1999 Mar; 19(1):27-30. PubMed ID: 10096721
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differentiating drugs by harm potential: the rational versus the feasible.
    Kalant H
    Subst Use Misuse; 1999 Jan; 34(1):25-34. PubMed ID: 10052388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adverse drug reactions. A problem for drug regulatory agencies.
    Westerholm B
    Int J Clin Pharmacol; 1973 Apr; 7(2):183-9. PubMed ID: 4731286
    [No Abstract]   [Full Text] [Related]  

  • 33. Adverse Drug Reactions Reported by Healthcare Professionals: Reaction Characteristics and Time to Reporting.
    Aung AK; Tang MJ; Adler NR; de Menezes SL; Goh MSY; Tee HW; Trubiano JA; Puy R; Zubrinich CM; Graudins LV
    J Clin Pharmacol; 2018 Oct; 58(10):1332-1339. PubMed ID: 29733431
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Attitudinal survey of adverse drug reaction reporting by medical practitioners in the United Kingdom.
    Belton KJ; Lewis SC; Payne S; Rawlins MD; Wood SM
    Br J Clin Pharmacol; 1995 Mar; 39(3):223-6. PubMed ID: 7619660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survey of the spontaneous adverse drug reaction reporting schemes in fifteen countries.
    Griffin JP
    Br J Clin Pharmacol; 1986; 22 Suppl 1(Suppl 1):83S-100S. PubMed ID: 3567037
    [No Abstract]   [Full Text] [Related]  

  • 36. Symposium on drug safety. The role of regulatory agencies and industry in assessment of the safety of drugs for use in man. The situation in the United Kingdom.
    Cahal DA
    Can Med Assoc J; 1968 Feb; 98(6):271-5. PubMed ID: 5636096
    [No Abstract]   [Full Text] [Related]  

  • 37. Case reports of suspected adverse drug reactions: case reports were dismissed too quickly.
    Vandenbroucke JP
    BMJ; 2006 Feb; 332(7539):488. PubMed ID: 16497772
    [No Abstract]   [Full Text] [Related]  

  • 38. Assessment of adverse reactions within a drug surveillance program.
    Borda IT; Slone D; Jick H
    JAMA; 1968 Aug; 205(9):645-7. PubMed ID: 5695107
    [No Abstract]   [Full Text] [Related]  

  • 39. Adverse drug reactions: the need for detection and control.
    Cluff LE
    Am J Epidemiol; 1971 Nov; 94(5):405-8. PubMed ID: 5120538
    [No Abstract]   [Full Text] [Related]  

  • 40. The Committee on Safety of Medicines.
    Goldberg A
    Health Bull (Edinb); 1981 Nov; 39(6):393-7. PubMed ID: 7035402
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.